期刊文献+

高效液相色谱法测定安立生坦片的有关物质 被引量:5

RP-HPLC Assay Method for Related Substances of Ambrisentan Tablets
原文传递
导出
摘要 目的建立安立生坦片有关物质的检测方法。方法采用高效液相梯度洗脱,色谱柱为Agela Venusil MP C18柱(4.6mm×250 mm,5μm),以0.02 mol·L-1磷酸二氢钾溶液(用磷酸调节p H至3.0)-乙腈(62∶38)为流动相A、乙腈为流动相B;流速为1.0 m L·min-1;检测波长为220 nm;柱温35℃。结果在酸、碱、热、氧化破坏条件下,安立生坦产生不同程度的降解,采用建立的方法可有效检出降解产物;安立生坦与各杂质分离良好,经验证该方法的专属性、线性、耐用性等良好。结论建立的方法可较好地分离、检测出安立生坦片中的各主要杂质,可用于本品有关物质的检查。 OBJECTIVE To establish an HPLC method for determination of the related substances of ambrisentan tablets.METHODS Gradient elution was performed on an Agela Venusil MP C18column( 4. 6 mm × 250 mm,5 μm). The mixture of 0. 02mol·L^-1phosphate buffer( p H 3. 0) and acetonitrile( 62∶ 38) was used as mobile phase A,and acetonitrile as mobile phase B. The flow rate was 1. 0 m L·min^-1; the detection wavelength was set at 220 nm; and the column temperature was maintained at 35 ℃. RESULTS After being treated with acid,base,heat,and oxidation,ambrisentan underwent more or less degradation. The method could effectively detect the degradation products of ambrisentan; the separation of impurities was good; the method had good specificity,linearity,and durability. CONCLUSION The proposed method can be used to separate and determine the related substances of ambrisentan tablets,and is suitable for the quality control of this drug.
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第6期541-544,共4页 Chinese Pharmaceutical Journal
关键词 安立生坦 有关物质 高效液相梯度洗脱 杂质G ambrisentan related substance HPLC gradient elution impurity G
  • 相关文献

参考文献6

  • 1刘文芳,傅得兴,胡欣.治疗肺动脉高压新药安贝生坦的药理与临床研究[J].中国新药杂志,2008,17(23):2070-2073. 被引量:6
  • 2Ch.P(2010)Vol Ⅱ(中国药典2010年版.二部)[S].2010:Appendix XC 85-87.
  • 3NAMASANI S K, AVULA P R, TELU V, et al. Extractive spec- trophotometric determination of ambrisentan [ J ]. Adv Pharm Bull, 2013, 3 ( 1 ) :231-237.
  • 4DOUSA M, GIBALA P. Rapid determination of ambrisentan enan- tiomers by enantioselective liquid chromatography using cellulose based chiral stationary phase in reverse phase mode [ J ]. J Sep Sci, 2012, 35 (7) :798-803.
  • 5NARAYANAL M B,CHANDRASEKHAR K B, RAO B M. A val- idated specific stability-indicating RP-HPLC assay method for am- hrisentan and its related substances[ J ]. J Chromatogr Sci. ,2014, 52(8) :818-825.
  • 6SFDA. Technical Guidelines for Chemical Drug Impurities (化学药物杂质研究的技术指导原则)[EB/OL].SFDA.2005.[2014-09].http://www.sfda.gov.cn/WS01/CL1616/83416.html.

二级参考文献24

  • 1BOLLI MH, MARFURT J, GRISOSTOMI C, et al. Novel benzo [ 1,4] diazepin-2-one derivatives as endothelin receptor antagonists[ J]. J Med Chem ,2004,47 ( 11 ) :2776 - 2795.
  • 2CLOZEL M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: Do they explain the long-term benefit? [J]. AnnMed,2003,35(8): 605 -613.
  • 3UHLMANN D, GABEL G, LUDWIG S, et al. Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/reperfusion[ J]. Microcirculation ,2005,12 ( 5 ) :405 - 419.
  • 4UHLMANN D, GLASSER S, GABEL G, et al. Improvement of postischemic hepatic microcirculation after endothelin A receptor blockade-endothelin antagonism influences platelet-endothelium interactions [ J ]. J Gastrointest Surg,2005,9 ( 2 ) : 187 - 197.
  • 5UHLMANN D, GABEL G, ARMANN B, et al. Attenuation of proinflammatory gene expression and mierocirculatory disturbances by endothelin A receptor blockade after orhotopic liver transplantation in pigs[ J]. Surgery,2006,139( 1 ) :61 -72,
  • 6GABEL G, UHLMANN D, TEUPSER D, et al. Influence of a selective endothelin (A) receptor antagonist on the quantitative mRNA expression and the immunohistochemishry of vasoactive mediators after pancreas transplantation [ J ]. Transplant Proc, 2003,35(6) :2137 -2138.
  • 7WITZIGMANN H, LUDWIG S, ESCHER E, et al. Administration of a selective endothelin-A receptor antagonist (BSF 208075) improves hepatie warm ischemia/reperfusion injury in pigs [ J ]. Transplant Proc,2002,34 ( 6 ) : 2387 - 2388.
  • 8KIRCHENGAST M. Endothelin receptor blockade and in-stent restenosis[ J ]. J Cardiovasc Pharmacol, 2001,38 ( Suppl 2 ) : S31 - S34.
  • 9KIRCHENGAST M, LUZ M. Endothelin receptor antagonists: Clinical realities and future directions[ J]. J Cardiovasc Pharmacol,2005,45(2) :182 - 191.
  • 10REMUZZI G, PERICO N, BENIGNI A. New therapeutics that antagonize endothelin : Promises and frustrations [ J ]. Nat Rev Drug Discov,2002, 1 (6) : 986 - 1001.

共引文献7

同被引文献19

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部